Jacob D. Soumerai

Hematology

55 Fruit St
Boston, MA 02114

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Journal: Blood advances

Published: February 24, 2026

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

Journal: Blood

Published: February 05, 2026

Developing MRD as an early endpoint for accelerated approval in CLL.

Developing MRD as an early endpoint for accelerated approval in CLL.

Journal: Seminars in hematology

Published: February 01, 2026

Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis.

Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis.

Journal: Leukemia & lymphoma

Published: November 18, 2025

A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter Transformation.

A phase I/II Study of Duvelisib plus Venetoclax in Patients with Relapsed/Refractory CLL/SLL or Richter Transformation.

Journal: Blood advances

Published: November 04, 2025

A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation.

A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation.

Journal: Blood advances

Published: November 04, 2025

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma.

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma.

Journal: Journal of hematology & oncology

Published: August 27, 2025

Triplet Therapies in Chronic Lymphocytic Leukemia.

Triplet Therapies in Chronic Lymphocytic Leukemia.

Journal: Hematology/oncology clinics of North America

Published: July 24, 2025

A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.

A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.

Journal: Blood advances

Published: May 13, 2025

A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphoma.

A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphoma.

Journal: Blood neoplasia

Published: May 05, 2025

Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy.

Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy.

Journal: Blood

Published: February 24, 2025

Polatuzumab vedotin extravasation injury: a case report.

Polatuzumab vedotin extravasation injury: a case report.

Journal: Leukemia & lymphoma

Published: January 25, 2025

Showing 1-12 of 54

Last Updated: 09/26/2026